期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

艾司西酞普兰合用匹维溴胺治疗肠易激综合征的临床疗效 被引量：2

下载PDF
导出
摘要 目的:观察艾司西酞普兰合用匹维溴胺治疗肠易激综合征(IBS)的临床疗效。方法:128例IBS患者,随机分为对照组30例及治疗组98例。对照组采用匹维溴胺治疗,50mg/次,3次/天;治疗组在此基础上服用艾司西酞普兰,10mg/次,1次/天。治疗8周后进行疗效比较。结果:治疗8周后治疗组症状改善总有效率(94.90%)明显高于对照组(73.33%)(P<0.05)。结论:艾司西酞普兰合用匹维溴胺治疗IBS有较好疗效。
作者 谭德虎
机构地区 湖北省巴东县人民医院
出处 《微循环学杂志》 2011年第2期60-61,I0002,共3页 Chinese Journal of Microcirculation
关键词 艾司西酞普兰 匹维溴胺 肠易激综合征 疗效
分类号 R971 [医药卫生—药品] R574.4 [医药卫生—消化系统]
  • 相关文献

参考文献9

  • 1刘新光.肠易激综合征与罗马Ⅲ诊断标准[J].胃肠病学,2006,11(12):736-738. 被引量：280
  • 2Pae CU,Masand PS,Ajwani N,et al.Irritable bowel syndrome in psychiatric perspectives:a comprehensive review.Int J Clin Pract,2007,61(10):1 708-1 718.
  • 3Videlock EJ,Chang L.Irritable bowel syndrome:current approach to symptoms,evaluation,and treatment.Castroenterol Clin North Am,2007,36(3):665-685.
  • 4Guthrie E,Barlow J,Fernandes L,et al.Changes in tolerance to rectal distension correlate with changes in psychological state in patientswith severe iritable bowel syndrome.Psyehosom Med,2004,66(41):578-582.
  • 5Talley NJ.Antidepressants in IBS:are we deluding ourselves?Am J Gastroenterol,2004,99(5):921-923.
  • 6Croom KF,Plosker GL.Spotlight on the pharmaeoeconomics of escitalopram in depression.CNS Drugs,2004,18(7):469-473.
  • 7Fabre V,Hamon M.Mechanisms of action of antidepressants:new data from Eseitalopram.Encephale,2003,29(3):259-265.
  • 8Mnie-Filali O,EI Mansari M,Scarna H,et a1.Escitalopram:Aselective inhibitor and allosteric modulator of the serotonin transporter.Encephale,2007,33(6):965-972.
  • 9Khan A,Bose A,Alexopoulos GS,et a1.Double-blind compar ison of escitalopram and duloxetine in the acute treatment of major depressive disorder.Clin Drug Investig,2007,27(7):481-492.

二级参考文献11

  • 1Drossman DA.Psychosocial and psychophysiologic mechanisms in GI Ⅲ ness.In:Kirsner JB,ed.The growth of gastroenterologic knowledge in the 20th century.Philadelphia:Lea & Febiger; 1993.41～432.
  • 2Whitehead WE,Palsson O,Jones KR.Systematic review of the comorbidity of irritable bowel syndrome with other disorders:what are the causes and implications? Gastroenterology,2002,122:1140～1156.
  • 3Drossman DA,Camilleri M,Mayer EA,Whitehead WE.AGA technical review on irritable bowel syndrome.Gastroenterology,2002,123:2108～2131.
  • 4Lea R,Whorwell PJ.New insights into the psychosocial aspects of irritable bowel syndrome.Curr Gastroenterol Rep,2003,5:343～350.
  • 5Drossman DA.The functional gastrointestinal disorders and the Rome Ⅲ process.Gastroenterology,2006,130:1377～1390.
  • 6Longstreth GF,Thompson WG,Chey WD,Houghton LA,Mearin F,Spiller RC.Functional bowel disorder.Gastroenterology,2006,130:1480～1491.
  • 7O'Donnell LJ,Virjee J,Heaton KW.Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate.BMJ,1990,300:439～440.
  • 8Longstreth GF,Drossman DA.Severe irritable bowel and functional abdominal pain syndromes:managing the patient and health care costs.Clin Gastroenterol Hepatol,2005,3:397～400.
  • 9Chey WD,Chey WY,Heath AT,Dukes GE,Carter EG,Northcutt A,Ameen VZ.Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.Am J Gastroenterol,2004,99:2195～2203.
  • 10Muller-Lissner S,Holtmann G,Rueegg P,Weidinger G,Loffier H.Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.Aliment Pharmacol Ther,2005,21:11～20.

共引文献279

同被引文献23

  • 1李文迁.西酞普兰治疗肠易激综合征46例[J].中国新药与临床杂志,2005,24(7):529-531. 被引量：4
  • 2德罗斯曼.罗马Ⅲ:功能性胃肠病[M]//柯美云,方秀才,译.第3版.北京:科学出版社,2008.
  • 3Francis C Y,Morris J,Whorwell P J.The Irritable bowel severity scoring system:a simple Method of monitoring irritable bowel syndrome and Its Progerss[J].Aliment Pharmacol Ther,1997,11(2):395.
  • 4Santicioli P,Zagorodnyuk V,Renzetti A R,et al.Antimuscarinic calcium channel blocker and tachykinin NK2 receptor antagonist actions of otilonium bromide in the circular muscle of guinea pig colon[J].Naunyn Schmiedebtrgs Arch Pharmacol,1999,359(5):420-427.
  • 5Evangelista S.Otilonium bromide:a selective spasmolytic for the gastrointestinal tract[J].J Int Med Res,1999,56(27):207-222.
  • 6Battaglia G,Morselli-Labate A M,Camrri E,et al.Otilonium bromide in the irritable bowel syndrome:a double-blind,placebo controlled,15 weeks study in a large number of patients[J].Aliment Pharmacol Ther,1998,12(10):1003-1010.
  • 7Ford A C,Talley N J,Schoenfeld P S,et al.Efficacy of antidepressants and psychological therapies in irritable bowel syndrome:systematic review and meta-analysis[J].Gut,2009,75(58):367-378.
  • 8Croom K F,Plosker G L.Spotlight on the pharmaeoeconomics of escitaloparm in depression[J].CNS Drugs,2004,18(7):469-473.
  • 9Fabre V,Hamon M.Mechanisms of action of antidepressants:new data from Eseitalopram[J].Encephale,2003,29(3):259-265.
  • 10Croom K F,Plosker G L.Spotlight on the pharmaeoeconomics of escitalopram in Jepression[J].CNS Drugs,2004,18(7):469-473.

引证文献2

二级引证文献9

微循环学杂志
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部